Xconomy Boston – Matthew Sherman, chief medical officer of Acceleron Pharma (NASDAQ: XLRN), plans to retire from the Cambridge, MA-based drug developer. Acceleron says Sherman won’t step away until after the company releases initial data from the Phase 3 study for luspatercept, a drug it is testing in partnership with Celgene (NASDAQ: CELG) as a treatment for a rare type of anemia.
Name: Matthew Sherman
Continent: North America
Company: Acceleron Pharma
Position: Chief Medical Officer
Announcement Date: January 24, 2018, 11:00pm
Resignation Date: January 24, 2018, 11:00pm